Notification of IVDs

Device Registration

The registration of devices according to Art. 90 IvDO will become mandatory in swissdamed as of July 1, 2026, with a transition period until December 31, 2026. Device registration

The registration obligation applies to devices under the existing legislation (IvDO) and to devices under the old legislation according to Art. 82 IvDO (“legacy devices”), which continue to be placed on the market at the time the registration obligation enters into force.

The registration obligation replaces the notification obligation by 1st July 2026.

The notification obligation remains in place for the following IVD devices:

  • Repackaged or relabelled IVDs according to art. 46 para. 4 and art. 47 para. 4 IvDO
  • IVDs manufactured and used in healthcare institutions according to art. 10 IvDO

From 1 January 2027, only notifications of individual devices may be submitted.

IVD (in-vitro diagnostic) medical devices

Manufacturers domiciled in Switzerland or in Liechtenstein are obliged to notify Swissmedic when they place IVDs on the market in Switzerland and/or in Liechtenstein for the first time. The legal basis for this obligation is Art. 90 para. 1 of the Ordinance on In Vitro Diagnostic Medical Devices (IvDO; SR 812.219) in conjunction with Art. 6 of the Medical Devices Ordinance of 17 October 2001 (oMedDO). Original copies of the standardised notification forms must be sent to Swissmedic, together with any other required additional documents.

IVDs in classes D, C, B and A sterile must be notified individually. The following documents should be submitted to Swissmedic:

  • certification documents relating to the conformity assessment procedures (EC certificates), and
  • the instructions for use plus – in the case of devices for self-testing and for near-patient testing –the layout of the outer packaging.

IVDs in class A (non-sterile) can be notified individually or as device groups. The following form for this purpose must be submitted to Swissmedic:

Repackaged or relabelled IVDs

The notification obligation, based on Art. 46 para. 4 and Art. 47 para. 4 IvDO, applies to persons (importers and distributors) domiciled in Switzerland or in Liechtenstein before the IVDs are placed on the market. The following form for this purpose must be submitted to Swissmedic:

The product list template for notifying a device group can be downloaded here:

IVDs manufactured and used in healthcare institutions

This concerns IVDs manufactured and used solely within a healthcare institution (in-house IVD) according to Art. 9 IvDO. In-house IVDs must be reported to Swissmedic according to Art. 10 IvDO. The notification obligation applies to healthcare institutions in Switzerland or in Liechtenstein prior to putting the devices into service.

The notification obligation referred to in Art. 10 IvDO applies to the following (examples, list not exhaustive):

  • Medical analytical test procedures developed in-house and implemented with own (non-CE-marked) reagents (e.g. a PCR test procedure for detecting a certain analyte)
  • Medical analytical test procedures based on standard procedures or published procedures and implemented with own (non-CE-marked) reagents
  • Test procedures acquired but not intended for medical use (e.g. "Research Use Only/RUO" procedures) that were (further) developed by the healthcare institution for medical analytical use
  • IVD instruments manufactured in-house
  • IVD software developed in-house

The notification obligation referred to in Art. 10 IvDO does not apply to the following (examples, list not exhaustive):

  • Test procedures with CE-marked IVDs that are implemented according to the directions of the IVD manufacturers
  • IVDs for performance studies
  • Products for general laboratory use
  • Products intended for research use only

Document MDCG 2023-1 on the European Commission website (Guidance - MDCG endorsed documents and other guidance (europa.eu)) contains further information on in-house IVDs.

The following form (guidelines for completion: see FAQ) must be sent to Swissmedic:

The product list template for notifying a device group can be downloaded here:

FAQ – Notification of in-vitro diagnostic medical devices

The information sheet provides answers to frequently asked questions relating to the notification of in-vitro diagnostic medical devices.

Specific questions regarding transmission of information and data protection

Encrypted e-mail communication via IncaMail
The Medical Devices divisions at Swissmedic offer encrypted e-mail communication via IncaMail.
This encrypted communication channel will be available on request. To use it, please get in touch with your contact person at Swissmedic.
IncaMail will facilitate the secure transmission of messages in conformity with data protection regulations. Further information on IncaMail can be found here.